Sandu Pharmaceuticals Ltd — Dividend/Bonus, 11-08-2026: Corp. Action

Sandu Pharmaceuticals' board has approved its financial results for the quarter ended June 30, 2026, reporting revenue from operations of approximately 16.39 Cr and a profit of about 0.23 Cr. The board also approved the annual report for the financial year 2025-26. For the upcoming 41st Annual General Meeting on September 11, 2026, the record date for dividend eligibility is September 4, 2026. Shareholders will consider continuing material related party transactions and the appointment of M/s. Dave & Dave as statutory auditors for five years.